Androgen Deprivation Therapy Market Report 2026

Androgen Deprivation Therapy Market Overview

• Androgen Deprivation Therapy market size has reached to $8.31 billion in 2025 • Expected to grow to $11.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Rising Prostate Cancer Cases Fueling The Growth Of The Market Due To Increasing Aging Population • Market Trend: Advancements In Oral Androgen Receptor Inhibitor Therapies Improve Treatment Convenience And Outcomes In Prostate Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Androgen Deprivation Therapy Market?

Androgen deprivation therapy is a treatment method that reduces or suppresses the activity of male hormones in the body to limit the growth of hormone-dependent cells. These hormones play a crucial role in various physiological processes, and lowering their presence can significantly influence cellular functions and biological responses. The main types of androgen deprivation therapy include medicine, surgery, and others. Medicine in ADT involves the use of drugs to reduce or block the production of androgens. It offers different routes of administration, including injectable and oral, and is used for various patient demographics, such as men aged 40-60, men aged 61-75, and men above 75. It is applied for prostate cancer and others by several end-users, including hospitals, specialty clinics, and others.

What Is The Androgen Deprivation Therapy Market Growth Forecast?

The androgen deprivation therapy market size is expected to see strong growth in the next few years. It will grow to $11.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to development of novel anti-androgen drugs, increasing investment in gene and immunotherapies, rising geriatric male population, growth in specialty clinics and hospital oncology departments, integration of digital monitoring and telehealth solutions. Major trends in the forecast period include rising adoption of lhrh agonists and antagonists, increased use of combination and targeted therapies, expansion of minimally invasive surgical procedures, growing focus on patient-specific and age-based treatments, enhanced monitoring and follow-up care for prostate cancer patients.

Global Androgen Deprivation Therapy Market Segmentation

1) By Type: Medicine, Surgery, Other Types 2) By Route Of Administration: Injectable, Oral 3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75 4) By Application: Prostate Cancer, Other Applications 5) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies 2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy 3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

What Is The Driver Of The Androgen Deprivation Therapy Market?

The increasing incidence of prostate cancer is expected to fuel the growth of the androgen deprivation therapy market in the coming years. Prostate cancer originates in the prostate gland, a part of the male reproductive system responsible for producing seminal fluid. Its incidence is climbing mainly due to longer life spans, as older age significantly raises the risk of developing the disease. Androgen deprivation therapy (ADT) is a primary treatment modality for prostate cancer, aimed at lowering androgen levels that drive tumor growth. It is frequently utilized in advanced or metastatic stages to delay disease progression. For instance, in January 2025, according to a report published by Prostate Cancer UK, a UK-based prostate cancer research, awareness, and support organization, in England, the number of prostate cancer diagnoses increased from 50,751 cases in 2022 to 55,033 cases in 2023, indicating a clear rise in annual incidence. Therefore, the increasing incidence of prostate cancer is driving the growth of the androgen deprivation therapy industry.

Key Players In The Global Androgen Deprivation Therapy Market

Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.

Global Androgen Deprivation Therapy Market Trends and Insights

Major companies operating in the androgen deprivation therapy (ADT) market are focusing on developing advanced solutions, such as oral androgen receptor inhibitors (ARIs), to provide more convenient, tolerable, and effective treatment options for patients with prostate cancer. Oral ARIs are targeted therapies that directly block androgen receptor activity in prostate cancer cells, preventing tumor growth without requiring frequent clinic-administered hormone-suppressing injections. For instance, in June 2025, Bayer AG, a Germany-based multinational pharmaceutical company, received US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI used in combination with ADT for treating metastatic hormone-sensitive prostate cancer (mHSPC). Designed to improve clinical outcomes and patient quality of life, Nubeqa inhibits androgen receptor signaling with high binding affinity, demonstrates minimal blood–brain barrier penetration to limit central nervous system side effects, and showed a 46% reduction in the risk of radiological progression or death compared to placebo plus ADT, according to the Phase III ARANOTE trial.

What Are Latest Mergers And Acquisitions In The Androgen Deprivation Therapy Market?

In February 2025, Tempus, a US-based health technology company, partnered with Artera to bring Artera’s advanced prostate cancer risk assessment test, ArteraAI Prostate Test, to market. This collaboration aims to enhance the accuracy of cancer prognosis by using artificial intelligence to support more informed medical decisions. As a result, ArteraAI's advanced digital pathology test, included in the NCCN guidelines, will assist in identifying patients with intermediate localized prostate cancer who are more likely to benefit from short-term androgen deprivation therapy. Artera is a US-based digital health company.

Regional Insights

North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Androgen Deprivation Therapy Market?

The androgen deprivation therapy market consists of revenues earned by entities by providing services such as hormonal assessment, monitoring services, telehealth consultations, and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The androgen deprivation therapy market also includes sales of hormone monitoring test kits, implantable hormone delivery systems, topical hormone regulation products, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Androgen Deprivation Therapy Market Report 2026?

The androgen deprivation therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the androgen deprivation therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.